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Abstract
This report is a subgroup analysis of the hepatitis B surface antigen (HBsAg) positive patients from
1995 to 1999, based on the data from the Renal Registry of the Hospital Authority of Hong Kong,
which accounted for approximately 90% to 95% of all the patients on renal replacement therapy
(RRT) in Hong Kong. As of 31 December 1999, there were 452 HBsAg positive patients (66 per
million populations). During 1999, there were 96 new HBsAg positive patients (14 per million
populations [pmp]). Of all the patients on RRT, 10% were HBsAg positive. The median age of the
HBsAg positive patients on RRT was 49 years, and 28% were above 61-year-old. For new HBsAg
positive patients who commenced on RRT during 1999, the median age was 53 years, and 34%
were above 61-year-old. The major causes of renal failure of the prevalent patients were
glomerulonephritis (GN) (38%) and diabetes (17%). For the new patients who entered into the program
in 1999, the major causes of renal failure were diabetic nephropathy (27%) and proven GN (20%).
In the HBsAg positive patients on RRT, 4.5% also had chronic hepatitis C infection, and 21% were
diabetics. The modes of RRT for the HBsAg positive patients were peritoneal dialysis (PD) (60%),
hemodialysis (HD) (12%) and transplant (TX) (28%). Eleven percent, 9% and 10% of all the patients
on PD, HD, with kidney transplant were HBsAg positive respectively. During 1999, 9.3% of the
new patients with kidney transplant were HBsAg positive. The annual crude mortality rate for
1999 was 7.1% (7.7% for PD, 13.2% for HD and 3.2% with TX). The major causes of death were
infection (31%), cardiovascular disease (19%) and liver failure (9%). For cadaveric kidney transplants,
the 1- and 5-year patient survival with transplant were both 90%, with history of transplant were
both 73%. The 1- and 5-year graft survival were both 73% (censored) and 65% (not censored)
respectively. The data were compared with all patients on RRT regardless of HBsAg status.
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INTRODUCTION
Almost 15% of the Hong Kong population are hepatitis
B surface antigen (HBsAg) carriers. The provision of
renal replacement therapy (RRT), either dialysis or
transplantation (TX), for this group of patients deserves
special consideration. Herein, we report the data
summarized from the Hong Kong Renal Registry
database over the past 5 years.
PATIENTS AND METHODS
This Renal Registry report was based on the data from
the Renal Registry of the Hospital Authority of Hong
Kong, accounting for 90% to 95% of all the patients on
RRT in Hong Kong (1). In the present review, we
performed a subgroup analysis of the data of the HBsAg
positive patients from 1995 to 1999. Relevant
comparison was made with the data for all patients on
RRT (regardless of HBsAg status) (2). All clinical data
were censored on 31 December 1999.
The crude mortality rate was defined as the mortality
rate of all patients treated during the period of the report.
For graft survival, patient death with a functioning graft
was a censored observation in "censored survival" but
an event in "noncensored survival".
RESULT AND DISCUSSION
Prevalence and incidence of RRT
The prevalence and incidence of RRT of the HBsAg
positive patients from 1995 to 1999 were summarized
in figure 1.
As of 31 December 1999, 452 HBsAg positive patients
were on RRT. During 1999, there was a net 9% increase
in the number of HBsAg positive patients on RRT. In
comparison, the net increase for all patients on RRT was
7%. The prevalence of RRT for HBsAg positive patients
was 66 per million populations (pmp). In comparison,
the prevalence of RRT for all patients on RRT was 640
pmp.
During 1999, 96 new patients joined the RRT program
of the Hospital Authority. The incidence of end-stage
renal failure for HBsAg positive patients was 14 pmp.
The incidence for all patients on RRT was 113 pmp.
The percentage of patients on the RRT who were positive
for HBsAg between 1995 and 1999 was shown in
figure 2. As of 31 December 1999, 10% of all patients
on RRT were HBsAg positive. Over the past 5 years, the
percentage of all patients on RRT who were HBsAg
positive was unchanged. However, there was a
decreasing trend in the percentage of the patients on
peritoneal dialysis (PD), and an increasing trend in the
percentage of the patients on hemodialysis (HD) who
were HBsAg positive.
Age and gender
The age distribution was summarized in figure 3A and
B.  As of 31 December 1999, the median age of the
 !"#$%e_ë^ÖEHF NVVV !"#$%& TKNBE TKTB NPKOB !
PKOBF !"#$%&'(EPNBF !"#ENVBF !"#EVBF !"#$%& N R
 !"#$%&VMB !"#$%TPB !R !"#$%&'TPBEFSRBE
F !"#$%&'()Ee_ë^Ö !F !"#$%&'()*+,-./
Figure 1.  Number of prevalent cases and new cases of HBsAg
positive patients on RRT in Hong Kong. Prevalent cases were
censored on the last day of each year.
Figure 2.  Percentage of patients on all RRT and on the different
modes of RRT who were HBsAg positive.
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HBsAg positive patients was 49 years (HD 46 years, PD
56 years, TX 43 years). It was 3 years younger than the
median age of 52 for all patients (HD 52 years, PD 59
years, TX 43 years). Of the HBsAg positive patients,
28% were above the age of 61 years and 7% were above
71 years. This was similar to that for all patients (32%
and 9% respectively).
The median age of the new HBsAg positive patients in
1999 was 52 years (HD 42 years, PD 53 years). It was 7
years younger than the median age of 59 for all patients
(HD 46 years, PD 60 years). Of the new HBsAg positive
patients, 34% were above the age of 61 years and 13%
were above 71 years. This was lower than that for all
patients (45% and 15% respectively). The median age
of the new HBsAg positive transplant cases (performed
in Hong Kong) was 41 years.
The male-to-female ratio of HBsAg positive patients was
1:1.6 (PD, 1:1.3; HD, 1:1.8; TX, 1:2.3). There was a trend
of female predominance, especially for the patients with
transplant. This ratio was different from the overall RRT
population, in which the ratio is equal except for the
patients with transplant, which had a slight male
predominance (any RRT, 1:1.1; PD, 1:1; HD, 1:1.1; TX,
1.4:1).
Underlying renal disease
The underlying renal diseases for prevalent and new cases
in 1999 for the HBsAg positive patients and for all
patients on RRT were summarized in table 1. In
comparison with all patients on RRT, the incidence of
new case with proven glomerulonephritis (GN) was
lower (20% vs. 25%), while of unknown cause was
higher (39% vs. 23%) for the HBsAg positive patients.
There was no difference in the prevalence of biopsy
proven GN between the HBsAg positive patients and
for all patients on RRT.
For the HBsAg positive patients with GN, 47% had
primary GN, 6% had secondary GN, 5% had advanced
glomerulosclerosis, and 43% had suspected GN on
clinical ground but not proved by biopsy.
Among the biopsy-proven cases of primary GN, 47%
were IgA nephropathy, 15% focal segmental
glomerulosclerosis, 11% mesangiocapillary GN, 14%
membranous GN, and 5% crescentic GN. (Note: the
mesangiocapillary and membranous GN were classified
as primary rather than secondary GN by the physicians).
The secondary GN cases were mainly due to systemic
Figure 3.  Age distribution of HBsAg positive patients on RRT: (A)
prevalent cases on the last day of 1999; (B) new cases in the year
of 1999.
Table 1.  Primary underlying renal disease of HBsAg positive patients and all patients on RRT in 1999.
HBsAg positive patients on RRT All patients on RRT
Primary renal disease Prevalent cases1 New cases2 Prevalent cases1 New cases2
Glomerulonephritis 38% 20% 37% 25%
Infection and reflux nephropathy 1% 0% 3% 1%
Hereditary and congenital causes 6% 9% 5% 5%
Obstructive uropathy and urolithiasis 4% 1% 3% 2%
Hypertension and vascular causes 3% 4% 5% 6%
Diabetic nephropathy 17% 27% 18% 33%
Others 1% 0% 4% 0%
Unknown 30% 39% 27% 23%
1On the last day of 1999.
2In the year of 1999.
A
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lupus erythematosus.
The prevalence of diabetic nephropathy in the HBsAg
positive patients increased from 11% in 1995 to 17% in
1999. The percentage of new RRT cases due to diabetic
nephropathy also increased from 23% in 1996 to 27% in
1999.
Comorbid conditions
Hepatitis C infection
The prevalence of hepatitis C infection was on the
decreasing trend in the HBsAg patients over the past 5
years (Fig. 4A). As of 31 December 1999, 4.5% of the
HBsAg positive patients were also chronic hepatitis C
carriers. This was similar to the prevalence of 5% for all
patients on RRT.
Diabetes mellitus
The prevalence of diabetes mellitus was on the increasing
trend in the HBsAg patients over the past 5 years (Fig.
4B). Among the HBsAg positive patients in 1999, 21%
were diabetics. This was similar to the prevalence of 23%
for all patients on RRT.
RRT
Mode of RRT
On 31 December 1999, of the 452 HBsAg positive
patients on RRT, 60% were on PD, 12%HD, and 28%
had functioning kidney transplants (Fig. 5). The mode
of RRT was similar to that of RRT for all patients (57%
on PD, 13% on HD and 30% with TX). There was no
significant influence of the HBsAg status on the mode
of RRT.
During 1999, 96 patients who were not on any form of
RRT at any renal unit of the Hospital Authority joined
the RRT program of the Hospital Authority. Among these,
82 were on PD, 11 on HD, and three had kidney
transplantation.
Peritoneal dialysis
On 31 December 1999, 11% of all the patients on PD
were HBsAg positive. Of the HBsAg positive patients
on dialysis, 84% were on PD. This is similar to the 82%
for all patients on dialysis were on PD.
Hemodialysis
On 31 December 1999, 9% of all the patients on HD
were HBsAg positive. Of the hemodialysis machines at
the renal units of Hospital Authority, 10% were
designated for HBsAg positive patients (18 of the 177
hemodialysis machines).
Transplantation
On 31 December 1999, 10% of all the patients with
transplantation were HBsAg positive. Ninety-six HBsAg
positive patients were on the kidney transplant waiting
list. This was 9.7% of all the patients on the renal
transplant waiting list, and 29% of all the HBsAg positive
patients on dialysis. In comparison, 33% of all patients
on RRT were on transplant waiting list. There was a lower
Figure 4.  Comorbidity in HBsAg positive patients: prevalence of
(A) chronic hepatitis C infection, and (B) diabetes. PD = peritoneal
dialysis; HD = hemodialysis; TX = transplantation
Figure 5.  Point prevalence of different modes of RRT, as censored
on the last day of each year.
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Figure 7.  Outcome of kidney transplantation in HBsAg positive
patients as compared to the HBsAg negative patients: (A) patient
survival and (B) graft survival.
percentage of HBsAg positive patients being listed on
transplant waiting list despite the younger age of the
HBsAg positive patients. This may reflect the selection
criteria for transplantation at some of the centers.
However, over the past 5 years, increasing number of
patient (from 44 to 96) and percentage of the HBsAg
patients on dialysis (from 18% to 30%) were put onto
the transplant waiting list. The median age of the patients
was also on the rising trend (from 39 to 43 years).
Over the past 5 years, 8% (n=11) of the 137 cadaveric
kidney donors in Hong Kong were HBsAg positive.
During 1999, 15 HBsAg positive patients received
kidney transplantation. This was 9.3% of the total 161
patients who had kidney transplant during the period.
Of the 15 HBsAg positive kidney transplants, seven were
performed in Hong Kong (five were with cadaveric
kidneys and two with living related kidneys). The other
eight were performed overseas. In comparison, of the
total 161 transplants performed for all patients, 69 were
performed in Hong Kong (47 were with cadaveric
kidneys and 22 with living related kidneys). The other
92 were performed overseas.
Outcome indicators
Crude mortality rates
For the 12 months ending 31 December 1999, the crude
mortality rate for the HBsAg positive patients on all
modes of RRT was 7.1 % (7.7% for PD, 13.2% for HD,
and 3.2% with TX). This was roughly similar to the crude
mortality rate of 8% for all patients on RRT (10% for
PD, 13% for HD and 1.2% for TX), except that the crude
mortality was three times higher in the HBsAg positive
patients.
Figure 6.  Yearly crude mortality of HBsAg positive patients on
RRT from 1996 to 1999.
Table 2.  Cause of death for HBsAg positive patients on RRT in 1999.
PD HD TX All cases no. (%)
Cardiovascular disease 6 0  0 6 (19%)
Cerebrovascular disease 1 0 0 1 (3%)
Liver failure 2 0 1 3 (9%)
Infection 5 3 2 10 (31%)
Malignancy 1 1 0 2 (6%)
Termination of dialysis 1 0 0 1 (3%)
Others 1 3 0 4 (13%)
Unknown 4 0 1 5 (16%)
Sub-total 21 7 4 32
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The yearly crude mortality rates for HBsAg positive
patients on all modes of RRT from 1996 to 1999 were
8.0%, 6.9% 9.7% and 7.1% (Fig. 6). In comparison, the
crude mortality rates for all patients from 1996 to 1999
were 7%, 7%, 7% and 8%, respectively.
Cause of death
The causes of death of the HBsAg positive patients
during 1999 were summarized in table 2. The major
causes of death were infection (31%) and cardiovascular
disease (19%). Other important causes of deaths were
liver failure (9%) and malignancy (6%).
In comparison, the major causes of death for all patients
on RRT were infection (29%) and cardiovascular disease
(27%). Liver failure and malignancy accounted for 1%
and 3% respectively.
There were less cardiovascular and cerebrovascular
deaths in the HBsAg positive patients, which may be
due to the relatively younger age of the group. Death
from liver failure was higher in HBsAg positive patients
when compared with all patients (9% vs. 1%).
Dialysis patient and technique survival
The program for data analysis was not yet available.
Transplant patient and graft survival  (of transplants
performed in Hong Kong between 1 April 1995 and 31
March 1999).
For HBsAg positive living-related kidney transplants (n
= 2 only), 1-year patient and graft survivals were both
100%.
For HBsAg positive cadaveric kidney transplants (n =
12), 1- and 5-year patient survivals with transplant were
both 90%, survivals with history of transplant were both
73%. One- and 5-year censored graft survivals were both
73%, noncensored graft survivals were both 65% (Fig. 7).
In comparison, for the HBsAg negative cadaveric kidney
transplants (n = 143), 1- and 5-year patient survivals with
transplant were 98% and 90%, survivals with history of
transplant were 96% and 86%, respectively. One- and
5-year censored graft survivals were 92% and 88%,
noncensored graft survivals were 91% and 80%
respectively. Because of the small number of HBsAg
positive transplant, statistic analysis was not performed.
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